AstraZeneca

Why trials sponsored by AstraZeneca stopped, in this sample of ClinicalTrials.gov.

33 stopped trials with a clear reason; 76% ended for non-scientific reasons.

Trials

• Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib
  NCT06754761 · TERMINATED · funding business
  “A decision, based solely on business strategy, was taken to terminate study D533BC00002 on 22 December 2025, as the clinical development programme for ceralasertib has been discontinued.”
• A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
  NCT07060365 · WITHDRAWN · funding business
  “The study termination is based on Sponsor decision and is not related to any safety, efficacy or quality concerns.”
• Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone
  NCT06457854 · WITHDRAWN · slow accrual
  “1. Decentralized sites. 2. Lack of sites interest in the study. 3. Super estimate of potential patient numbers. 4. Transforming the protocol to a retrospective one could impact the study's publication timeline.”
• A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
  NCT06599502 · TERMINATED · funding business
  “The decision to cease enrolment and proceed with the early termination of the ALAFOSS 01 (D7080C00001) study was based on strategic company portfolio prioritization.”
• AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment
  NCT06611423 · TERMINATED · slow accrual
  “The Sponsor encountered difficulties in recruiting patients for clinical trial D8330C00004 and decided to end the study earlier for business reasons not affecting the benefit-risk balance.”
• Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
  NCT06231693 · TERMINATED · funding business
  “The study was stopped due to a realignment of strategic priorities”
• A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
  NCT05397171 · TERMINATED · safety
  “This study was terminated early as per protocol Section 4.4, based on overall risk-benefit profile observed to date. No safety concerns reported. Only Substudy 1 Part A was started; Parts B \& C were not started. Entire Master Protocol was terminated.”
• A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults
  NCT05057897 · TERMINATED · slow accrual
  “Removal of the commitment for Immune compromised study (D81111C00010) due to recruitment challenges.”
• A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
  NCT04949425 · TERMINATED · funding business
  “Study terminated because the clinical development programme for Adavosertib has been discontinued”
• Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia
  NCT04997161 · TERMINATED · other
  “There is disconnect between dietary guidelines to limit potassium intake in dialysis and clinical practice. The number of unknowns and differences make the results unlikely to be translatable into clinical practice and will not benefit patients.”
• A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
  NCT04492722 · TERMINATED · futility
  “The Sponsor decided to terminate the study early due to lack of efficacy. There were no safety concerns related to the study.”
• Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.
  NCT04199598 · TERMINATED · funding business
  “The decision to terminate has been taken by the Sponsor. The decision is not due to safety concerns but reflects business prioritizations of the company.”
• US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
  NCT04125290 · TERMINATED · slow accrual
  “Study stopped due to lack of recruitment.”
• Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.
  NCT03756285 · TERMINATED · funding business
  “A decision was made to stop the study early when AstraZeneca evaluated the available data and it was considered that completing the study would provide limited additional information and unlikely to change the study conclusions.”
• Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT03616821 · TERMINATED · funding business
  “Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.”
• A Phase IV Study in Drug-Naive Patients With T2DM in China
  NCT03344341 · TERMINATED · funding business
  “Study overall progress behind of scheduled timeline. Study was terminated early due to company decision.”
• The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
  NCT03152084 · TERMINATED · slow accrual
  “Poor recruitment.”
• AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  NCT02780830 · WITHDRAWN · slow accrual
  “Study D2276C00001 was not started. No patients were enrolled. The sponsor decided to pursue an alternate design.”
• A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer
  NCT02087176 · TERMINATED · funding business
  “The study was terminated early by the sponsor.”
• forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)
  NCT01944618 · TERMINATED · other
  “Participant Data obtained to 30Sep2015: Baseline data: 447 6 month data: 253 Program terminated: recruitment target not met. No analysis will be provided.”
• Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
  NCT01838499 · TERMINATED · futility
  “At the planned IA for decision making, no evidence was demonstrated of MEDI8968 activity in reducing (HS) severity or pain over that seen with placebo.”
• Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
  NCT01569074 · TERMINATED · funding business
  “AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.”
• To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension
  NCT01403922 · TERMINATED · funding business
  “Sponsor's decision to terminate”
• Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart
  NCT01359618 · TERMINATED · funding business
  “Sponsor decision to terminate”
• Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy
  NCT01128114 · TERMINATED · slow accrual
  “Poor recruitment”
• A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765
  NCT01130909 · TERMINATED · other
  “The benefit of halting the study to analyze the available data outweighs the benefit of delaying the analysis to include data from remaining treatment periods”
• ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer
  NCT00929162 · TERMINATED · futility
  “Primary objective of the trial was not met and so there was no benefit in collecting further information”
• Seroquel XR in Adults With Schizophrenia
  NCT00852631 · TERMINATED · slow accrual
  “The study was prematurely terminated due to insufficient recruitment.”
• Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
  NCT00660595 · TERMINATED · slow accrual
  “To difficult to recruit patients in the acute setting”
• Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies
  NCT00805467 · TERMINATED · funding business
  “AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.”
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
  NCT00626548 · TERMINATED · futility
  “early efficacy review by the Independent Data Monitoring Committee indicated it was unlikely to meet its primary efficacy endpoints”
• Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients
  NCT00139074 · TERMINATED · slow accrual
  “terminated due to very low recruitment rate (27 June 2006)”
• GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes
  NCT00252876 · TERMINATED · funding business
  “The development program has been terminated”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.